Catalan Institution for Research and Advanced Studies Barcelona Spain

Center of Molecular Biology and Gene Therapy Department of Internal Medicine Hematology and Oncology University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic

Center of Molecular Medicine Central European Institute of Technology Masaryk University Brno Czech Republic

Hematology Department Hospital Clínico Universitario of Valladolid Valladolid Spain

Hematology Department Hospital Universitario Salamanca Salamanca Spain

IBSAL IBMCC Cancer Research Center University of Salamanca Salamanca Spain

Research Programon Biomedical Informatics IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra Barcelona Spain

Zobrazit více v PubMed

Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013;5:47. doi: 10.1186/gm451. PubMed DOI PMC

Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526:519–24. doi: 10.1038/nature14666. PubMed DOI

Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–30. doi: 10.1038/nature15395. PubMed DOI PMC

Ljungstrom V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood. 2016;127:1007–16. doi: 10.1182/blood-2015-10-674572. PubMed DOI PMC

Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589. doi: 10.1038/ncomms11589. PubMed DOI PMC

Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon KA, et al. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015;5:e303. doi: 10.1038/bcj.2015.14. PubMed DOI PMC

Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018;10:25. doi: 10.1186/s13073-018-0531-8. PubMed DOI PMC

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60. doi: 10.1182/blood-2017-09-806398. PubMed DOI

Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, et al. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018;32:450–61. doi: 10.1038/leu.2017.230. PubMed DOI PMC

Messina M, Del Giudice I, Khiabanian H, Rossi D, Chiaretti S, Rasi S, et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood. 2014;123:2378–88. doi: 10.1182/blood-2013-10-534271. PubMed DOI PMC

Van Damme V, Govaerts E, Nackaerts K, Dooms C, Wauters I, Vansteenkiste J. Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. Lung Cancer. 2013;79:73–6. doi: 10.1016/j.lungcan.2012.09.015. PubMed DOI

Cazzola M. IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications. Haematologica. 2010;95:1623–7. doi: 10.3324/haematol.2010.030015. PubMed DOI PMC

Mansouri L, Sutton LA, Ljungstrom V, Bondza S, Arngarden L, Bhoi S, et al. Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015;212:833–43. doi: 10.1084/jem.20142009. PubMed DOI PMC

Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119:2854–62. doi: 10.1182/blood-2011-12-395673. PubMed DOI

Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473–9. doi: 10.1200/JCO.2009.27.8762. PubMed DOI

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes